Polifarma Spa

What Polifarma Spa does

Polifarma Spa is an Italian pharmaceutical company founded in Rome in 1919, operating as a private SpA within the Final Holding group. The company develops and markets pharmaceutical products across five therapeutic verticals: central nervous system (including vertigo), gastroenterology, ophthalmology, cardiovascular, and infectious/respiratory diseases. Core marketed products include Almarytm (antiarrhythmic, handled via Viatris partnership), Icomb (ramipril-amlodipine combination for hypertension), and the Melatonina Pierpaoli line for sleep wellness. Distribution is conducted through a dedicated network of Pharmaceutical Sales Representatives (Informatori Scientifici del Farmaco) who provide medical-scientific information to specialists (cardiologists, gastroenterologists, ophthalmologists, neurologists) across Italy, supported by an ISO 9001 certified quality management system.

The company differentiates through a 'bio-digital' therapeutic model, coupling drugs with proprietary Digital Medical Devices currently in development: QK-D for hypertension management (co-developed with daVi Digital Medicine), DarSana for telecontrol of visual acuity in age-related macular degeneration, and ISO-D for guiding colonoscopy preparation alongside a macrogol-based bowel cleansing product. The website also offers a Salutepedia patient education platform and a Reserved Area for healthcare professionals.

The business model combines traditional one-time pharmaceutical product sales with subscription/recurring revenue potential from the digital therapeutics pipeline. In February 2025, Polifarma completed the acquisition of 100% of Germany's Hennig Arzneimittel GmbH & Co. KG, a 125+ year-old pharmaceutical company operating a CDMO with capacity exceeding 6 billion units annually and exports to 27+ countries, adding neurology, psychiatry, gastroenterology, and cardiology products plus contract manufacturing revenue. The deal transformed Polifarma into a multi-country European pharmaceutical group and earned the German M&A Award 2025 'Best Family Business Deal'.

Name

Polifarma Spa

Legal name

Polifarma SpA

Website

https://polifarma.it

Company type

Private

Founded year

1919

Operating status

Operating

Headcount range

51–100 employees

Short description

Polifarma Spa is an Italian pharmaceutical company founded in 1919 that develops and markets prescription drugs and digital therapeutics across cardiovascular, central nervous system, gastroenterology, ophthalmology, and respiratory therapeutic areas, serving specialists and patients in Italy and 27+ countries via a sales-rep network and recent German Hennig acquisition.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro industry

PRIMARYHLAIAAAE

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Pharmaceutical products
• Digital therapeutics
• Contract manufacturing
• Cardiovascular drugs
• Bio-digital therapies

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Traditional pharmaceutical products across therapeutic areas including cardiovascular, gastroenterology, central nervous system, ophthalmology, and infectious diseases. Products include Almarytm (arrhythmia treatment), Icomb (hypertension), and melatonin products.
2. Digital Therapeutics (DTx): Bio-digital therapies combining drug therapy with digital applications for chronic disease management including hypertension, ophthalmology, and gastroenterology.
3. CDMO Services: Contract Development and Manufacturing Organization services through subsidiary Hennig Arzneimittel.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Polifarma Spa is an Italian pharmaceutical company founded in 1919 and headquartered in Rome. The company develops, manufactures, and markets branded pharmaceutical products and digital therapeutics across cardiology, gastroenterology, central nervous system, ophthalmology, and infectious diseases. Its portfolio combines traditional drug formulations with proprietary digital medical devices/software-as-a-medical-device offerings.

Product overview

Polifarma Spa is an Italian pharmaceutical company established in 1919, operating as a 'Smart Pharma Company' that develops and markets pharmaceutical products and bio-digital therapies. The company offers a portfolio spanning five therapeutic areas: Central Nervous System, Gastroenterology, Ophthalmology, Cardiovascular, and Infectious Diseases/Respiratory. Product portfolio includes traditional pharmaceuticals (Almarytm for arrhythmias, Icomb for hypertension, Melatonina Pierpaoli for sleep wellness) and Digital Therapeutics (QK-D for hypertension, DarSana for AMD telecontrol, ISO-D for colonoscopy preparation). Following the February 2025 acquisition of Hennig Arzneimittel, the group now includes Polifarma S.p.A., Polifarma Benessere, and Hennig Arzneimittel GmbH & Co. KG.

Differentiator

Problem solved

Functional benefit

Products and services

• Almarytm

Quantifiable outcome

• Awarded German M&A Award 2025 - Best Family Business Deal
• +4 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• ViatriscoreStrategic or Co-development Partner · 1 April 2025Partnership for Almarytm, a reference molecule for arrhythmia treatment. Polifarma handles medical-scientific information for this product, expanding their cardiovascular portfolio.
• Hennig Arzneimittel GmbH & Co. KGcoreStrategic or Co-development Partner · 1 February 2025Polifarma acquired 100% of German pharmaceutical company Hennig Arzneimittel in February 2025. Hennig specializes in vertigo treatment, neurology, psychiatry, gastroenterology, and cardiology, and operates as a CDMO. The acquisition strengthens Polifarma's international presence and adds manufacturing capabilities with over 6 billion units annual capacity.
• Laife ReplycoreTechnology or Integration · 1 December 2024Collaboration for development of a new digital therapy for hypertension, combining pharmaceutical and digital solutions.
• daVi Digital Medicine S.r.l.coreTechnology or Integration · 1 December 2024Co-development of QK-D Digital Medical Device for hypertension treatment. daVi provides digital medicine expertise for the bio-digital therapeutic.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Chiesi Farmaceutici: Private Italian specialty pharmaceutical company with a comparable multi-therapeutic-area model (respiratory, neonatology, rare disease) and a parallel international expansion strategy. Polifarma overlaps with Chiesi on the pattern of an Italian family/private pharma building global specialty franchises.
• Dompé: Italian biopharmaceutical company with a portfolio spanning ophthalmology, primary care and rare diseases — overlapping Polifarma's ophthalmology (AMD/DarSana) and primary care franchises. Comparable as a privately-controlled Italian pharma investing in specialty innovation.
• Italfarmaco: Private Italian pharma with specialty and rare disease franchises, including cardiovascular and CNS overlap. Comparable to Polifarma as a similarly-sized privately-held Italian specialty pharma building international reach.
• Molteni Farmaceutici: Italian privately-held specialty pharma focused on pain/addiction/psychiatry with strong manufacturing capabilities. Comparable to Polifarma on size, ownership structure and the combination of branded pharma + domestic manufacturing expertise.
• Zambon: Italian family-owned pharma group operating across CNS, respiratory and pain with international manufacturing/CDMO elements. Highly comparable to Polifarma as another privately-controlled Italian mid-cap pharma pursuing therapeutic diversification and global expansion.
• Recordati: Public Italian specialty pharma with strong cardiovascular/urology/endocrinology franchises — directly comparable to Polifarma's Almarytm/Icomb cardiovascular focus — and a track record of cross-border European bolt-on M&A analogous to Polifarma's Hennig deal.
• Menarini Group: Italy's largest privately-held pharma group with a similarly broad therapeutic footprint spanning cardiology, oncology, gastroenterology, and anti-infectives. Comparable to Polifarma as a privately controlled Italian pharma leveraging a wide portfolio plus international expansion through acquisitions.
• Angelini Pharma: Italian family-owned pharma (part of Angelini Industries) with CNS, pain and consumer health portfolios. Directly comparable to Polifarma on the family/private ownership model and CNS therapeutic overlap (Polifarma's vertigo/SNC area).

Emerging players

• Voluntis: Digital therapeutics company developing software-based treatments for chronic conditions including oncology and diabetes. Comparable to Polifarma's QK-D, DarSana and ISO-D as an emerging DTx player pursuing similar pharma-partnered commercialization models.

Broad incumbents

• Stada Arzneimittel: German-headquartered specialty and generics pharma with significant CDMO operations and pan-European distribution — directly comparable to the Hennig Arzneimittel business Polifarma just acquired. Larger and broader than Polifarma but the most direct benchmark for the German CDMO/international leg of the group's strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/polifarmaspa

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polifarma Spa